Enterococcus News and Research

RSS

Universal Gown And Glove Use By Health-Care Workers In ICU Reduces MRSA 40 Percent

Healthcare workers' use of disposable gowns and gloves upon entering all patient rooms on an intensive care unit (ICU), versus only in rooms on standard isolation protocol, helped reduce patient acquisition of methicillin-resistant Staphylococcus aureus (MRSA) by approximately 40 percent, according to new research co-led by the University of Maryland School of Medicine and the Yale New Haven Health System Center for Healthcare Solutions.

5 Oct 2013

Researchers identify novel mechanism that particular superbug uses to fend off antibiotic

Investigators working to stem the spread of antibiotic-resistant bacteria have taken a major step in their efforts to develop new treatments.

29 Aug 2013

Kansas researchers defeat persistent bacteria known for causing infections in hospitals

Kansas State University researchers are defeating persistent bacteria known for causing infections in hospitals.

19 Jul 2013

Sequella licenses Pfizer's exclusive worldwide rights to develop, commercialize sutezolid

Sequella, a clinical-stage pharmaceutical company commercializing novel antibiotics to treat life-threatening infectious diseases, today announced that it has licensed Pfizer Inc's exclusive worldwide rights to develop and commercialize sutezolid, a Phase 2 oxazolidinone antibiotic currently in development for the treatment of tuberculosis.

17 Jul 2013

University of Granada researchers patent new treatment for acne

University of Granada scientists have patented a new treatment for acne that is based on completely natural substances and is much more effective than artificial formulas because it does not create resistance to bacteria and has no secondary effects.

23 May 2013

Cubist receives Fast Track designation from FDA for late-stage antibiotic candidate

Cubist Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted the Company's late-stage antibiotic candidate ceftolozane/tazobactam (CXA-201) Fast Track status in the previously granted Qualified Infectious Disease Product indications, Hospital-Acquired Bacterial Pneumonia/Ventilator-Associated Bacterial Pneumonia and Complicated Urinary Tract Infections.

8 May 2013

Cempra demonstrates solithromycin's potential against urogenital infections at ECCMID

Cempra, Inc., a clinical-stage pharmaceutical company focused on developing differentiated antibiotics to meet critical medical needs in the treatment of bacterial infections, today announced that it will present data at the European Congress of Clinical Microbiology and Infectious Diseases in Berlin, demonstrating solithromycin's potential to treat urogenital infections and combat challenging pathogens such as enterococci and Legionella pneumophila.

29 Apr 2013

Study shows copper objects in ICUs reduce healthcare-acquired infections by 50%

Placement of copper objects in intensive care unit (ICU) hospital rooms reduced the number of healthcare-acquired infections (HAIs) in patients by more than half, according to a new study published in the May issue of Infection Control and Hospital Epidemiology, the journal of the Society for Healthcare Epidemiology of America, in a special topic issue focused on the role of the environment in infection prevention.

10 Apr 2013

Left-sided brain injury increases infection risk

Patients with a left-sided brain injury are more likely to develop hospital-acquired infections than those with right-sided injury, show study findings.

5 Mar 2013

Cubist receives FDA QIDP designation for ceftolozane/tazobactam to treat HABP/ VABP, cUTI

Cubist Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has designated the company's late-stage antibiotic candidate, ceftolozane/tazobactam, as a Qualified Infectious Disease Product (QIDP) for the indications of Hospital-Acquired Bacterial Pneumonia (HABP)/Ventilator-Associated Bacterial Pneumonia (VABP) and Complicated Urinary Tract Infections (cUTI).

1 Mar 2013

Reintroducing normal microbial diversity can eliminate VRE from intestinal tracts

Too much antibiotic can decimate the normal intestinal microbiota, which may never recover its former diversity. That, in turn, renders the GI tract vulnerable to being colonized by pathogens. Now researchers from Memorial Sloan-Kettering Cancer Center, New York, NY, and Centro Superior de Investigaci-n en Salud P-blica, Valencia, Spain, show that reintroducing normal microbial diversity largely eliminated vancomycin-resistant enterococci (VRE) from the intestinal tracts of mice..

28 Feb 2013

Chlorhexidine bathing protects vulnerable hospital patients

Bathing hospital patients with chlorhexidine-impregnated washcloths reduces the risk for them acquiring multidrug-resistant organisms and developing bloodsteam infections, show study findings.

7 Feb 2013

Feeding human breast milk to very-low-birth-weight infants reduces risk of sepsis and NICU costs

Feeding human breast milk to very-low-birth-weight infants greatly reduces risk for sepsis and significantly lowers associated neonatal intensive care unit (NICU) costs, according to a study by Rush University Medical Center researchers.

6 Feb 2013

Enterococcal cytolysin synthetase helps form distinctly different, 3-D protein ring structures

While working out the structure of a cell-killing protein produced by some strains of the bacterium Enterococcus faecalis, researchers stumbled on a bit of unusual biochemistry. They found that a single enzyme helps form distinctly different, three-dimensional ring structures in the protein, one of which had never been observed before.

23 Jan 2013

Bacteriophages may play an important role in competition among bacterial strains

Unique viruses called bacteriophages may play an important role in competition among bacterial strains, influencing the overall ecosystem of the human intestine, scientists at The University of Texas at Arlington and UT Southwestern Medical Center say.

11 Dec 2012

FDA designates two of Cubist’s Phase 3 antibiotic candidates

Cubist Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has designated two of the company's Phase 3 antibiotic candidates, CXA-201 (ceftolozane/tazobactam) and CB-315, as Qualified Infectious Disease Products (QIDP).

6 Dec 2012

Metalloacid surfaces may be answer to hospital-acquired infections

Coating surfaces in metalloacids may help control the spread of hospital-acquired infections, suggest study findings.

14 Nov 2012

Researchers figure out 3D shape of promising TB drug target

Researchers at Johns Hopkins have figured out the three-dimensional shape of the protein responsible for creating unique bonds within the cell wall of the bacteria that cause tuberculosis. The bonds make the bacteria resistant to currently available drug therapies, contributing to the alarming rise of these super-bacteria throughout the world.

26 Oct 2012

Screening practices for multidrug-resistant organisms in ICUs vary widely between hospitals

Screening practices for multidrug-resistant organisms (MDROs) in intensive care units (ICUs) vary widely from hospital to hospital, according to a new study by researchers at Columbia University School of Nursing and published in the October 2012 issue of the American Journal of Infection Control.

16 Oct 2012

Screening practices for multidrug-resistant organisms in ICUs vary widely between hospitals

Screening practices for multidrug-resistant organisms (MDROs) in intensive care units (ICUs) vary widely from hospital to hospital, according to a new study published in the October issue of the American Journal of Infection Control, the official publication of the Association for Professionals in Infection Control and Epidemiology (APIC).

29 Sep 2012

Enterococcus News and Research

Universal Gown And Glove Use By Health-Care Workers In ICU Reduces MRSA 40 Percent

Researchers identify novel mechanism that particular superbug uses to fend off antibiotic

Kansas researchers defeat persistent bacteria known for causing infections in hospitals

Sequella licenses Pfizer's exclusive worldwide rights to develop, commercialize sutezolid

University of Granada researchers patent new treatment for acne

Cubist receives Fast Track designation from FDA for late-stage antibiotic candidate

Cempra demonstrates solithromycin's potential against urogenital infections at ECCMID

Study shows copper objects in ICUs reduce healthcare-acquired infections by 50%

Left-sided brain injury increases infection risk

Cubist receives FDA QIDP designation for ceftolozane/tazobactam to treat HABP/ VABP, cUTI

Reintroducing normal microbial diversity can eliminate VRE from intestinal tracts

Chlorhexidine bathing protects vulnerable hospital patients

Feeding human breast milk to very-low-birth-weight infants reduces risk of sepsis and NICU costs

Enterococcal cytolysin synthetase helps form distinctly different, 3-D protein ring structures

Bacteriophages may play an important role in competition among bacterial strains

FDA designates two of Cubist’s Phase 3 antibiotic candidates

Metalloacid surfaces may be answer to hospital-acquired infections

Researchers figure out 3D shape of promising TB drug target

Screening practices for multidrug-resistant organisms in ICUs vary widely between hospitals

Screening practices for multidrug-resistant organisms in ICUs vary widely between hospitals

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News